Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv
In the mass spectrometry lab: Biologist Mathias Sauer (seated) shows mass spectra for Associate Professor Johan Gobom, Professor Henrik Zetterberg and Associate Professor Gunnar Brinkmalm (standing). Photo: Elin Lindström.

Towards improved diagnostics for several types of dementia

4 May, 2022 Leave a Comment

GRANT. Twenty years of research have culminated in blood tests that can be used for clinical diagnosis of Alzheimer’s disease. Henrik Zetterberg, professor of neurochemistry, has just been awarded the European Research Council’s prestigious Advanced Grant to establish similar markers for other forms of dementia.

Long-term research into clinical neurochemistry at the University of Gothenburg has resulted in three well-established cerebrospinal fluid markers that are used around the world to determine early on whether a person has Alzheimer’s. These have now been developed into reliable blood tests. However, of all those experiencing symptoms of neurodegenerative diseases, only half of them have Alzheimer’s. This means that for many people, it is not possible to test to determine which underlying disease is specifically responsible for failing memory or other cognitive problems – unless they are caused by Alzheimer’s.

Five-year plan

As the researchers develop tests for other forms of dementia, focus will lie on frontotemporal dementia and Lewy body dementia.

Henrik Zetterberg. Photo: Elin Lindström.

“If all goes to plan, within five years we should have markers for more forms of dementia that can be measured in cerebrospinal fluid or maybe even in the blood. These can then be used in clinical procedures,” says Henrik Zetterberg, professor at the University of Gothenburg and chief physician at Sahlgrenska University Hospital.

He has just been awarded one of the most prestigious grants a researcher can receive. The European Research Council’s Advanced Grant provides him and the major research group he leads with Kaj Blennow with SEK 25 million for the next five years.

Considerably more complex

As with Alzheimer’s, frontotemporal dementia and Lewy body dementia are characterized by proteins in the brain failing to work as they should or binding together, thus interrupting the nerve cells’ function. Previous attempts to develop biomarkers for these types of dementia have been unsuccessful. This is likely because changes to the tissue are not as evident in bodily fluids as is the case with Alzheimer’s.

Doctoral student Joel Simrén and Professor Henrik Zetterberg next to one of the measuring instruments that will be used in the project. Photo: Elin Lindström.

“We are aware that we are embarking on an incredibly complex project, but the timing is right. The development of highly sensitive measuring methods in mass spectrometry and immunochemistry has given us the right conditions. Furthermore, we have gained great experience from our previous successes with Alzheimer’s markers,” says Henrik Zetterberg.

The project will also develop new methods for measuring the activation of different types of brain cell–astrocytes and microglia–in neurodegenerative diseases. It is becoming increasingly clear that these brain cells play a more important role in the progression of dementia than researchers previously thought. These methods will be of good use as dementia research around the world continues.

The brain, cerebrospinal fluid, blood

Henrik Zetterberg also holds a professorship at University College London, where the research group has access to a large biobank containing brain tissue donated by people with dementia after their death. The research team will dissolve the brain tissue and analyze changes to identify molecules, which will then be further examined in cerebrospinal fluid and blood. Previous research has shown that there are two good candidates for the new potential biomarkers, alpha-synuclein for Lewy body dementia and Parkinson-like conditions, and TDP-43 pathology for certain forms of frontotemporal dementia and amyotrophic lateral sclerosis, ALS.

An ethical dilemma

The research group faces an ethical dilemma as they create ways to diagnose incurable diseases. Patients may find it hard to find out they have a disease where little can be done to cure it or slow down its progression.

Henrik Zetterberg. Photo: Elin Lindström.

“Nevertheless, we are convinced that the biomarkers that reflect the process behind different forms of dementia will speed up the development of medication. This will enable pharmaceutical companies to recruit the right patients, measure the extent to which their product on trial actually affects the disease, and analyze blood or cerebrospinal fluid to measure the progression of the disease after three, six, and twelve months of treatment.

Hopefully, the new methods will facilitate rapid and accurate diagnosis, which has been shown to be positive for patients seeking medical care following concern about symptoms.

At the same time, it is important that patients who have been diagnosed receive good support to be able to cope and are not abandoned by the system,” says Henrik Zetterberg.

There are several antibody-based treatments on the way for Alzheimer’s that use antibodies to reduce the plaque on the brain that characterizes the disease. One such treatment has recently been approved in the USA, however the positive effects on cognitive functioning appear to be limited.

Good help from the Grants and Innovation Office

The Grants and Innovation Office played a decisive role in the application to the European Research Council, ERC, in particular Research Advisor Dubi Eliasson and Finance Officer Tinna Carlsson.

“Applying for ERC support requires an enormous amount of work. Furthermore, few applications are successful.” This summer, when I realized it was time to start my application, it felt overwhelming. All the encouragement, help, and feedback from the Office made all the difference. Without that, I would probably have taken out vacation days,” says Henrik Zetterberg.

BY: ELIN LINDSTRÖM

 

 

By: Elin Lindström
Tagged With: Alzheimers sjukdom, Bidrag och stipendier, Bidrag och stipendier, institutionen för neurovetenskap och fysiologi

Leave a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Add your own events in the Akademiliv Calendar

The Akademiliv newsletter has paused for summer. In the autumn, you will receive the first regular newsletter on August 24th.

Collected links regarding the war in Ukraine

We are building at Medicinareberget

You will now find comprehensive information on construction projects that affect the Sahlgrenska Academy in the Staff Portal.

Lunch menus

Café & restaurang Anatomen

Gastronomen på SU

Lunchen.nu

Lyktan lunchservering

Lustgården på Änggårdsbacken

Café Anne Dahl

More news

Summer wishes from Dean Agneta Holmäng

23 June, 2022

CHRONICLE. In her last letter to staff and students this semester, Agneta Holmäng focuses especially on two matters that caused a big flurry of …  

The University’s work with research areas

22 June, 2022

PROFILE AREAS. Which areas should be designated as special research areas at the University of Gothenburg? This issue will be investigated in the …  

See Natrium from the inside – open tour September 30

22 June, 2022

The construction project invites staff and students at the Faculty of Science and Sahlgrenska Academy on September 30 in the afternoon. With less …  

Magnet makes life science research visible at the Swedish NMR centre

21 June, 2022

CONDITIONS OF RESEARCH. Outside the Swedish NMR Centre, at the Hasselblad laboratory on Medicinareberget, a large magnet has recently been set …  

Nominate members to the consultative assembly for election of a vice-chancellor

20 June, 2022

VICE-CHANCELLOR ELECTION. Sahlgrenska Academy will appoint 13 members to the consultative assembly, which is preparing the appointment of a …  

Stem cells can become a treatment for common joint disease

20 June, 2022

RESEARCH COOPERATION. In the future, it is hoped that stem cells can be used to treat osteoarthritis, the world’s most common joint disease. R …  

Innovation from within when Vinnova visited Gothenburg

20 June, 2022

INTERACTION. Life science and collaboration among the medical system, academia, and the private sector was the main theme when Vinnova, Sweden’s i …  

Protein Research: Increased Access to Knowledge and Support

16 June, 2022

CONDITIONS OF RESEARCH. With Protein Production Sweden (PPS), a new national infrastructure has taken shape. Expression, production and …  

New episode of the Swedish podcast Akademiliv – with diabetes researcher Emanuel Fryk

16 June, 2022

PODCAST. Guest in this episode of the podcast Akademiliv is Emanuel Fryk, a doctoral student at the University of Gothenburg and a doctor at a …  

Primary hyperparathyroidism linked to bone fracture, stroke, and heart attack

16 June, 2022

NEW STUDY. In the hormonal disorder primary hyperparathyroidism, patients’ risk of hip fracture is elevated by 51%, and that of heart attack or s …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen